There are currently 119 clinical trials in Anchorage, Alaska looking for participants to engage in research studies. Trials are conducted at various facilities, including Providence Alaska Medical Center, Katmai Oncology Group, Alaska Women's Cancer Care and Anchorage Oncology Centre. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
NCT05610163
Recruiting
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +6 locations
Conditions: Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Register for Updates
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265
Recruiting
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +6 locations
Conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Katmai Oncology Group - Anchorage, Anchorage, Alaska
Conditions: Breast Cancer
Register for Updates
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236
Recruiting
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Alaska Women's Cancer Care, Anchorage, Alaska
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +7 locations
Conditions: Plasma Cell Myeloma
Register for Updates
The Sequestration of Holistic Stress Management Techniques for Adults
NCT06098755
Recruiting
This remote study is intended to assist the population with access to cost-effective pastoral counseling for stress management in the workplace and every day life. In awareness of a support system, Bachelor's age 30 and older requirements were waived to accept the Bachelor's age 21-29 for verified relatives of an individual Humanitarian Veterans Association member; however, without BLOOD-QUANTUM to an individual Humanitarian Veterans Association member, the preferred Bachelor age is 30 years old... Read More
Gender:
MALE
Ages:
21 years and above
Trial Updated:
05/23/2025
Locations: Virtual Tribunal Monastery, Anchorage, Alaska
Conditions: Stress, Job
Register for Updates
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Katmai Oncology Group, Anchorage, Alaska
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
05/15/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +6 locations
Conditions: Ovarian Carcinoma
Register for Updates
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT06388018
Recruiting
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Alaska Women's Cancer Care, Anchorage, Alaska
Conditions: Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC V8
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/15/2025
Locations: Alaska Heart and Vascular Institute, Anchorage, Alaska
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +5 locations
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
Register for Updates